Preclinical results showing synergistic activity of hLL1-DOX with PIs and IMiDs provide the biological rationale for the evaluation of this ADC in combination with other agents
Preclinical results showing synergistic activity of hLL1-DOX with PIs and IMiDs provide the biological rationale for the evaluation of this ADC in combination with other agents. 4. the front-line and relapse settings. Other antibodies targeting numerous antigens are under evaluation. B cell maturation antigens (BCMAs), selectively expressed on plasma cells, emerged as a encouraging target…